



KEY FACTS

Investment Objective

The Fund's objective is to generate investment returns by investing in companies that are focused on the growth in consumption and services in emerging markets. The portfolio provides exposure to this philosophy through active stock picking based on a fundamental bottom-up approach with disciplined analytics and an awareness of macro factors. The focus is on growth companies, which are domiciled, or carrying out the main part of their economic activity, in an emerging market country. The Fund is suitable for investors seeking long term capital appreciation.

Fund Information

FUND TYPE	Commingled Fund
LEGAL FORM	Limited Partnership
CUSTODIAN	The Bank of New York
ADMINISTRATOR	The Bank of New York
AUDITOR	Grant Thornton
DOMICILE	Delaware, USA

INCEPTION DATE	1st April 2021
FUND SIZE	\$21.4m
STRATEGY SIZE	\$514.8m
INDEX	MSCI TR Net Emerging Markets USD
PRICING FREQUENCY	Monthly
MANAGERS	Andrew Dalrymple, John Ewart, Rob Brewis

MANAGER'S COMMENTARY

After a strong start to the month, buoyed by a sharp rebound in India, enthusiasm faded and the Fund gave back those gains and ended down 1.5% while the index was up slightly. The major positive from the month was continued strength in China, which as the largest market, bodes well for the entire emerging market asset class.

The correction in India which had begun in October continued in February despite what we thought was a positive budget, the easing of oil prices, as well as a more dovish tone and a first rate cut from the RBI. The GDP number for the quarter to December also confirmed an upturn in growth to 6.5%, confirming that the previous quarter's sub-6% as an anomaly as we had expected. Government expenditure rebounded, as did the consumer. For now, this positive news is being ignored, although we doubt for that much longer as valuations are now as cheap as they have been since early 2023, and the prospects look to us still highly positive.

Although we remain highly confident about our Indian portfolio, we have made a few changes, one being the sale of the remainder of our **Varun Beverages**. This has been a standout performer over the 6 years it has been in the portfolio, rising ten-fold at its peak and adding over 10% to portfolio returns. Through much of last year we sold down the position on valuation grounds and have now decided the arrival of an aggressive competitor in the form of Reliance's Campa Cola is grounds for stepping aside for now. In its place, we have returned to leading finance company, **Bajaj Finance**, which has been significantly de-rated in recent years, and now looks very attractively valued.

The combination of trades and performance now sees China as a larger weight than India in the portfolio for the first time in 2 years. As the Deepseek news sinks in, there appears to have been a reassessment of Chinese prospects and valuations in the technology sector. This is no more obvious in our best performing stocks of the month: **BYD**, **Xiaomi** and **Tencent**. A simple valuation comparison between these and their US comparisons (Tesla, Apple and Meta) makes a stark case in favour of the Chinese. No more so than in **BYD's** case, which looks to have much better growth prospects and for 18x PE, rather than Tesla's 69x. A **Xiaomi** v Apple comparison is perhaps more of a stretch, but at least **Xiaomi** managed to make a car the people seem to want, with the new Ultra version selling out on launch.

The only disappointment in China was **Trip.com** which reported an encouraging set of results albeit with further investments in its international operations as it takes on the likes of Booking.com in South East Asia. **BYD** also raised \$5bn by selling HK listed H shares in order to finance their overseas production growth, causing a temporary price correction. Both clear examples of Chinese globalisation which appears somewhat immune to the trade war escalating around it.

We have highlighted the success of the Indian government in attracting domestic and foreign investment in recent years. Employment creation, income growth, and consumer confidence are all welcome developments. Parallels can be drawn with the well publicised meeting of President Xi with various Chinese business leaders during the month and was seen as an endorsement of the private sector in their development of technology and economic opportunities for the country. Clearly, government support which encourages consumer optimism and a return in spending behaviour to support these broader trends in China are to be welcomed.

NET PERFORMANCE

CUMULATIVE %	1M	3M	6M	1Y	3Y	INCEPTION
Fund Return	-1.5	-5.5	-4.5	-0.9	-4.0	-16.3
Index Return	0.5	2.1	0.4	10.1	1.4	-9.4

CALENDAR YEAR %	2024	2023	2022
Fund Return	11.6	9.4	-26.1
Index Return	7.5	9.8	-20.1

Source: Aubrey Capital Management, MSCI & BNYM

Past performance is not a reliable indicator of future results and you may not get back what you originally invested and investment returns may increase or decrease as a result of currency fluctuations. Calendar year performance refers to full calendar years.


PORTFOLIO BREAKDOWN

Top 10 Positions

Company	% of Holding
Taiwan Semiconductor	6.3
Xiaomi	5.5
Mercadolibre	5.0
Trip.Com	4.5
Trip.Com	4.4
Sea Ltd	4.0
MakeMyTrip	3.8
MediaTek	3.7
Bharti Airtel	3.6
Max Healthcare	3.6
Number of Holdings	30


The securities identified and described do not represent all of the securities purchases, sold or recommended for client accounts. The reader should not assume that an investment in the securities identified was or will be profitable.

Sector Allocation



Consumer Discretionary	30.5
Information Technology	21.6
Financials	16.5
Communication Services	12.2
Industrials	7.0
Consumer Staples	5.4
Health Care	3.5
Real Estate	3.3

Geographic Allocation



China	33.0
India	30.9
Taiwan	15.2
Singapore	10.9
Brazil	5.2
South Korea	3.1
Chile	1.7

CONTACTS

Investment Enquiries

EMAIL	clientservices@aubreycm.co.uk
TELEPHONE	+44 (0) 131 226 2083

Head Office

ADDRESS	Aubrey Capital Management Limited 10 Coates Crescent Edinburgh EH3 7AL
---------	---

IMPORTANT INFORMATION

Aubrey Capital Management Limited is authorised and regulated by the Financial Conduct Authority and registered as an Investment Adviser with the US Securities & Exchange Commission. No offer is made to buy or sell any security or investment product. This is not a solicitation to invest in any investment product of Aubrey Capital Management Limited. Investors in the strategy are exposed to fluctuations in the value of investments, which can go down as well as up, may be subject to significant volatility due to market conditions and changes in foreign exchange rates. The benchmark is an index, the performance of which is not affected by fees and expenses like the strategy. Past investment performance is not an indication of future performance. The Fund aims to invest all its assets in emerging market equities which have a higher than average risk when compared to investing in more established markets as investments may be affected by local market conditions. As a result of these risks, you should ensure investment in the Fund is suitable for you. If you are still unsure, seek independent professional advice.

Aubrey Capital Management has taken reasonable care to ensure the accuracy of this information at the time of publication but it is subject to change without notice and it does not in any way constitute investment advice or an offer or invitation to deal in securities.

MSCI: The MSCI information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.msci.com).

[Please click here to access the Fund's documentation.](#)